


**BACKGROUND DENSITY  
TARGET**



**Hoffmann-La Roche Inc.**

$\Delta \pi$  EXHIBIT 593  
Deponent KWOK  
Date 8/10/06 Rptr. SFB  
[WWW.DEPOBOOK.COM](http://WWW.DEPOBOOK.COM)

NOTEBOOK NO. 4489  
ISSUED TO SHIRLEY KWOK  
ON Feb 21 19 91  
DEPARTMENT Infectious Diseases  
RETURNED \_\_\_\_\_ 19 \_\_\_\_\_

—SCIENTIFIC NOTEBOOK CO.—  
2831 LAWRENCE AVE.  
P.O. BOX 238  
STEVENSVILLE, MI 49127  
616-429-8285

66


Project No. \_\_\_\_\_  
Book No. \_\_\_\_\_

TITLE Generation of shuffle sequence

From Page No. \_\_\_\_\_

73

Andy J  
GPO



Digested 25 ul of product in PstI/Bsa

5 ul 10x High Salt  
25 ul Product  
1 ul PstI  
1 ul Bam  
18 ul g.d.H<sub>2</sub>O

37°C for 2 hrs

Given to N.M for cloning into sp6 vector

To Page No. 66

Witnessed & Understood by me,

PS Walsh

Date

8/6/91

Invented by

Recorded by

J Lee

Date

7/3/91

Witness

TITLE Proposal for Quantitative Assay Project No. \_\_\_\_\_  
Book No. \_\_\_\_\_ 67

From

Current Status of the HIV-2 Assay and a Proposal for Development  
of an HIV RNA PCR Quantitative Assay (S Kwok)

The HIV-1 and HTLV assays developed in our lab are currently being finalized at RDS. As of May 27, 1990, our lab has focused primarily on developing an assay for HIV-2. Since the HIV-2 project was initiated last year, we have encountered two major obstacles.

First, sample procurement has been a problem. The CDC has provided us with some HIV-2 samples. However, these are few and far between. Furthermore, the amount of DNA we receive for each sample is generally enough for only a few reactions which poses a problem when dealing with recalcitrant samples. We have recently initiated a collaboration with Dr. Varnier at the University of Genova in Italy. We received 50 HIV-2 samples from his group but many of these samples were not PCR competent as determined by HLA amplifications. Once again, the quantity of material was insufficient for extensive studies. The ability to obtain large quantities of well-characterized HIV-2s is absolutely critical to the success of this project. Once a good candidate primer pair has been identified, validation of the primers will require yet another batch of samples.

Second, the HIV-2 genomes are more heterogeneous than the HIV-1s and selection of a primer pair-probe system that amplifies all isolates has been a challenge. To date, sequence information is available for only 7 HIV-2s. Three SIV isolates, a virus closely related to HIV-2, have been sequenced. Despite identifying regions that are highly conserved (which are few), we have only been able to detect 80% of the isolates with our best primer pair. It appears that the sequenced isolates may represent but a fraction of those present in the population. Furthermore, HIV-2 isolates from different parts of Africa may be divergent.

Witnessed & Understood by me,

Date

Invented by

Date

Recorded by

68

Project No. \_\_\_\_\_

Book No. \_\_\_\_\_

TITLE \_\_\_\_\_

TITLE

From

The incorporation of HIV-2 into the HIV-1 assay has obvious appeal. HIV-2 has been observed primarily in West Africa and to date, only a handful of individuals in the United States have been infected with this virus. These individuals were either from West Africa or had contracted the disease there. Serological and peptide assays for HIV-2 are available. In addition, given the problems with sample procurement and the heterogeneity of the virus, I feel we need to reevaluate the priority given to the HIV-2s.

I propose that rather than devote the entire lab to HIV-2, that we begin to develop a procedure for quantitation of HIV-1 viral load in infected patients. Our effort on HIV-2 would be decreased but not terminated. There is a huge demand for quantitative assays to evaluate drug efficacy. A quantitative assay for HIV RNA by PCR would fill this need.

**CONSIDERATIONS:**

In developing a quantitative HIV RNA assay we need to take into consideration every aspect of the procedure, from sample preparation to amplicon detection

- A) Selection of a sample preparation protocol. Ideally, the sample preparation protocol should be easy to use and require only a few manipulations. Microprobe's and HRI's extraction procedures are simple, but the efficiency of sample recovery needs to be assessed.
- B) Reverse transcription and PCR. Reverse transcription and PCR will be performed in a single tube with the Tth DNA polymerase. To the extent possible, reactions will be pretreated with UNG and amplified in the presence of dUTP.

Witnessed & Understood by me,

Date

Invented by

Date

Recorded by

Witness

TITLE \_\_\_\_\_

Project No. \_\_\_\_\_

Book No. \_\_\_\_\_

69

FR

possible, reactions will be pretreated with UNG and amplified in the presence of dUTP.

C) Cycling. For accurate quantitation, the range of exponential amplification as a function defined cycle number needs to be determined.

D) Detection. Ideally, the detection method should be non-radioactive, have a sensitivity of  $10^7$  molecules, and have a broad dynamic range (1-1000 input molecules). It would be best if a colorimetric microtiter detection format similar to that currently used at Roche could be employed. The current HRP detection method has a very narrow range (1-15 input molecules) with the amplification profiles currently in place due to PCR plateau. The dynamic range for detection of amplicons in the microtiter format is between  $10^7$ - $10^8$  molecules (R. Pottahil). By modifying the amplification profile we should be able to establish a linear range of detection. Competition between Watson-Crick strands may interfere with probe capture and an asymmetric amplification system may be required. Alternatively, given the efficiency and specificity of the SK462-431 system with UNG pretreatment at 50°C, we may be able to quantitate with fluorescence alone. Stephen Scharf and Steve Will recommended using fluorescent tagged primers (ROX or JOE). ABI claims attamole sensitivity with both labels.

E) Standards.

Page No. \_\_\_\_\_

Witnessed & Understood by me, \_\_\_\_\_

Date \_\_\_\_\_

Invented by \_\_\_\_\_

Date \_\_\_\_\_

Recorded by \_\_\_\_\_

70

Project No. \_\_\_\_\_

Book No. \_\_\_\_\_

TITLE \_\_\_\_\_

TITLE \_\_\_\_\_

Fi

Fi

1. Internal standard to monitor sample recovery. We need to first determine whether intracellular genomic RNA, viral particulate RNA, or mRNA should be targeted. For intracellular genomic and mRNA, we might consider co-amplification of a 'housekeeping' gene. For viral particles, perhaps we could spike in an exogenous, non-human virus such as MuLV. This virus would have inserted into a non-functional part of its genome, the SK462 and SK431 primer binding sites and a modified internal HIV sequence (see below).

Potential pitfalls with using MuLV:

- a. Maintaining a stock of intact viruses.
  - b. Quantitation of viral particles as there will be defective viruses and empty capsids
  - c. Amplification of MuLV may not necessarily reflect condition of HIV particles in the specimen.
2. Internal standard to follow RT and PCR efficiencies. If MuLV or other "mutated" virions are not used, RNA transcripts containing the same primer binding sites but with a modified internal sequence, can be spiked into the reactions. The internal sequence should be sufficiently different so that it can be differentiated from the true target. Several approaches can be taken. These include, a) replacement of the SK102 probe region with "junk" sequences; b) complete scrambling of the internal sequence; or c) Alice Wang's HIV plasmid which spans the SK145-39 region and contains a single point mutation leading to creation of a new restriction endonuclease site within the SK38-39 region. Some of the potential disadvantages in using Alice's control are: 1) restriction endonuclease cleavage is required to differentiate between control and true

Page No. \_\_\_\_\_

Witnessed & Understood by me,

Date

Invented by

Date

Recorded by

Witness

Project No. \_\_\_\_\_

Book No. \_\_\_\_\_

71

TITLE \_\_\_\_\_

Fr

target; 2) heterodimers that form can abolish restriction sites (very likely especially at high input number); 3) potential mutation in the true target that generates same restriction endonuclease site (much less likely).

**STRATEGY:**

Development of this assay will have to occur as a multi-step process, some of which can occur concurrently:

1. Given the uncertainties of using MuLV as control, we will construct a randomized clone of the region flanked by SK462-431 for use as an internal standard. The SK462-431 region can be depicted as 5 separate regions: A-E. Region A=SK462, B=region between A and SK102; C=SK102; D=region between SK102 and SK431; and E=SK431. Our strategy is to retain the primer binding sites A and E, but shuffle regions B, C, and D each separately and then combine, rather than shuffle the internal sequences altogether. The intent is to maintain the location, sequence composition, and Tm of the SK102 probe region.
  
2. The shuffled sequences will be generated by ligation and repair of two long oligonucleotides that overlap by 6 bases of complementarity at the 3' terminus. The first oligonucleotide contains a *Pst*I linker, the SK462 region, and the first half of the shuffle sequence. The second oligonucleotide contains a *Bam*HI linker sequence, the SK431 region, and the complement of the second half of the shuffle sequence. After annealing and subsequent repair with Klenow, the fragment will be digested with *Pst*I and *Bam*HI and cloned into a transcription vector, pSP64 (with poly A).

Witnessed & Understood by me,

Date

Invented by

Date

Recorded by

No.



72

Project No. \_\_\_\_\_

Book No. \_\_\_\_\_

TITLE \_\_\_\_\_

TITLE

Fro

Fro

3. After cloning and isolation of plasmid DNA, the DNA will be linearized and transcribed *in vitro* with SP6 RNA polymerase. To remove residual DNA, the RNA will be passed through an oligo dT column and further digested with RNase free DNase.
  
4. For quantitation, various amounts of RNA will be spiked into the extracted samples. Control and sample RNA will be reversed transcribed with either *Tth* DNA polymerase or MuLV RT. The decision on whether *Tth* DNA polymerase or MuLV RT will be used depends on *Tth*'s ability to incorporate dUMP in the one-step reaction and on the relative importance *Tth* vs carryover prevention. Single step RT/PCR that incorporates dUTP/UNG can be performed with MuLV and *Taq* DNA polymerase but without the benefit of RT at elevated temperature. The internal standard will serve as control for reverse transcription as well as PCR.
  
5. Attempts will be made to identify reaction conditions which will allow preferential amplification of RNA over DNA. For example, given the relatively low melting temperature of our amplicons (75°C for SK38-39 and 86°C for SK462-431) over complex DNA, we may be able to modify the denaturation profiles to bias amplification of the amplicon. Since RNA-DNA hybrids are more stable than DNA-DNA hybrids, one potential problem is identifying denaturation conditions which will selectively allow denaturation of the transcribed cDNA from RNA while keeping the duplex DNA intact.

This potential problem can be minimized in at least three ways. One, which we already have in place for HIV, is to design systems where the amplicons have lower melting temperatures. Since the downstream primer will be used to reverse

No. \_\_\_\_\_

Witnessed & Understood by me,

Date

Invented by

Date

Recorded by

Witness

TITLE \_\_\_\_\_ Project No. \_\_\_\_\_  
 Book No. \_\_\_\_\_ 73

Fr

transcribe from RNA, the "business" end of this potentially long transcript should still have a lower melting temperature which, hopefully will be "breathing" sufficiently to allow the second primer to anneal and extend in the first cycle of PCR at a lower than standard denaturation temperature. Second, RNase H can be added to degrade the RNA prior to PCR. Finally, modified bases that decrease in this duplex can also skew the reaction.

The HIVBX2 RNA transcripts generated by A. Wang's group and the HIVZ6 plasmid DNA generated by S-Y Chang, provides an attractive model system for evaluating RNA vs DNA amplifications. Minor sequence variations between these two viral variants has enabled us to design type specific probes that will further facilitate analysis.

6. A quantitative detection system that has a broad dynamic range needs to be developed. We will begin by evaluating amplifications with ROX and JOE (fluorescent) labeled primers and assess signal as a function of copy and cycle number. Products will be initially analyzed on ABI's gene scanner. Samples will be amplified with dUTP and reactions pretreated with UNG at 50°C for 2 minutes. If the results are promising, the assay can be converted to a microtiter plate capture format. In this format, the products can be analyzed on two different plates, each coated with either the shuffled SK102 (for the internal control) or with SK102. Alternatively, unlabeled primers can be used and the products captured with ROX (for internal control) and Joe (for true target) labeled probes. Only SK431 which is complementary to SK102 will be labeled. Several investigators have

Witnessed & Understood by me,	Date	Invented by	Date	No.
		Recorded by		

74

Project No. \_\_\_\_\_

Book No. \_\_\_\_\_

TITLE \_\_\_\_\_

From Page No. \_\_\_\_\_

reported increased signal detection when both primers were labeled -presumably due to network structures. A single-labeled primer may provide more accurate quantitation.

In this strategy, there are no internal controls to monitor sample recovery during the extraction procedure. In addition, while we will attempt to preferentially amplify RNA over DNA, the presence of any single-stranded DNA in the sample may compromise interpretation of the results.

To Page No. \_\_\_\_\_

Witnessed & Understood by me, \_\_\_\_\_

Date \_\_\_\_\_

Invented by \_\_\_\_\_

Date \_\_\_\_\_

Recorded by \_\_\_\_\_

TITLE \_\_\_\_\_

From P \_\_\_\_\_

WIT \_\_\_\_\_

TITLE Amplification - Joe & Rox labeled primers Project No. \_\_\_\_\_ Book No. \_\_\_\_\_

75

From Page No. Start

Nancy prepared ~~control~~ amplifications with Joe labeled primers & compared my earlier observation that Joe primers were less efficient. Repeated ~~exp~~ here on Qc4 with ~~dup/ung~~ <sup>(2exp)</sup>. Also compared ~~from~~ <sup>amplified</sup> Rox (che) labeled primers & compared ~~dup/ung~~ vs dTP.

	unlabeled	Joe	Rox labeled
	dTP	dTP	dTP
1	34	35	36
2	37	38	39
3	40	41	42
4	43	44	45
5	46	47	48
6	49	50	51
7	52	53	54
8	55	56	57
9	58	59	60
10	61	62	63
11	64	65	66
12	67	68	69
13	70	71	72
14	73	74	75
15	76	77	78
16	79	80	81
17	82	83	84
18	85	86	87
19	88	89	90
20	91	92	93
21	94	95	96
22	97	98	99
23	100	101	102
24	103	104	105
25	106	107	108
26	109	110	111
27	112	113	114
28	115	116	117
29	118	119	120
30	121	122	123
31	124	125	126
32	127	128	129
33	130	131	132
34	133	134	135
35	136	137	138
36	139	140	141
37	142	143	144
38	145	146	147
39	148	149	150
40	151	152	153
41	154	155	156
42	157	158	159
43	160	161	162
44	163	164	165
45	166	167	168
46	169	170	171
47	172	173	174
48	175	176	177
49	178	179	180
50	181	182	183
51	184	185	186
52	187	188	189
53	190	191	192
54	193	194	195
55	196	197	198
56	199	200	201
57	202	203	204
58	205	206	207
59	208	209	210
60	211	212	213
61	214	215	216
62	217	218	219
63	220	221	222
64	223	224	225
65	226	227	228
66	229	230	231
67	232	233	234
68	235	236	237
69	238	239	240
70	241	242	243
71	244	245	246
72	247	248	249
73	250	251	252
74	253	254	255
75	256	257	258
76	259	260	261
77	262	263	264
78	265	266	267
79	268	269	270
80	271	272	273
81	274	275	276
82	277	278	279
83	280	281	282
84	283	284	285
85	286	287	288
86	289	290	291
87	292	293	294
88	295	296	297
89	298	299	300
90	301	302	303
91	304	305	306
92	307	308	309
93	310	311	312
94	313	314	315
95	316	317	318
96	319	320	321
97	322	323	324
98	325	326	327
99	328	329	330
100	331	332	333
101	334	335	336
102	337	338	339
103	340	341	342
104	343	344	345
105	346	347	348
106	349	350	351
107	352	353	354
108	355	356	357
109	358	359	360
110	361	362	363
111	364	365	366
112	367	368	369
113	370	371	372
114	373	374	375
115	376	377	378
116	379	380	381
117	382	383	384
118	385	386	387
119	388	389	390
120	391	392	393
121	394	395	396
122	397	398	399
123	400	401	402
124	403	404	405
125	406	407	408
126	409	410	411
127	412	413	414
128	415	416	417
129	418	419	420
130	421	422	423
131	424	425	426
132	427	428	429
133	430	431	432
134	433	434	435
135	436	437	438
136	439	440	441
137	442	443	444
138	445	446	447
139	448	449	450
140	451	452	453
141	454	455	456
142	457	458	459
143	460	461	462
144	463	464	465
145	466	467	468
146	469	470	471
147	472	473	474
148	475	476	477
149	478	479	480
150	481	482	483
151	484	485	486
152	487	488	489
153	490	491	492
154	493	494	495
155	496	497	498
156	499	500	501
157	502	503	504
158	505	506	507
159	508	509	510
160	511	512	513
161	514	515	516
162	517	518	519
163	520	521	522
164	523	524	525
165	526	527	528
166	529	530	531
167	532	533	534
168	535	536	537
169	538	539	540
170	541	542	543
171	544	545	546
172	547	548	549
173	550	551	552
174	553	554	555
175	556	557	558
176	559	560	561
177	562	563	564
178	565	566	567
179	568	569	570
180	571	572	573
181	574	575	576
182	577	578	579
183	580	581	582
184	583	584	585
185	586	587	588
186	589	590	591
187	592	593	594
188	595	596	597
189	598	599	600
190	601	602	603
191	604	605	606
192	607	608	609
193	610	611	612
194	613	614	615
195	616	617	618
196	619	620	621
197	622	623	624
198	625	626	627
199	628	629	630
200	631	632	633
201	634	635	636
202	637	638	639
203	640	641	642
204	643	644	645
205	646	647	648
206	649	650	651
207	652	653	654
208	655	656	657
209	658	659	660
210	661	662	663
211	664	665	666
212	667	668	669
213	670	671	672
214	673	674	675
215	676	677	678
216	679	680	681
217	682	683	684
218	685	686	687
219	688	689	690
220	691	692	693
221	694	695	696
222	697	698	699
223	700	701	702
224	703	704	705
225	706	707	708
226	709	710	711
227	712	713	714
228	715	716	717
229	718	719	720
230	721	722	723
231	724	725	726
232	727	728	729
233	730	731	732
234	733	734	735
235	736	737	738
236	739	740	741
237	742	743	744
238	745	746	747
239	748	749	750
240	751	752	753
241	754	755	756
242	757	758	759
243	760	761	762
244	763	764	765
245	766	767	768
246	769	770	771
247	772	773	774
248	775	776	777
249	778	779	780
250	781	782	783
251	784	785	786
252	787	788	789
253	790	791	792
254	793	794	795
255	796	797	798
256	799	800	801
257	802	803	804
258	805	806	807
259	808	809	810
260	811	812	813
261	814	815	816
262	817	818	819
263	820	821	822
264	823	824	825
265	826	827	828
266	829	830	831
267	832	833	834
268	835	836	837
269	838	839	840
270	841	842	843
271	844	845	846
272	847	848	849
273	850	851	852
274	853	854	855
275	856	857	858
276	859	860	861
277	862	863	864
278	865	866	867
279	868	869	870
280	871	872	873
281	874	875	